文献速递胸部肿瘤

Bintrafusp Alfa靶向TGF-β与PD-L1在NSCLC二线治疗中的1期扩展队列结果

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
PubMed 文献 · J Thorac Oncol · 2020-03-13

该1期扩展队列纳入80例含铂治疗后进展且未接受过免疫治疗的晚期NSCLC患者,随机接受bintrafusp alfa 500 mg或1200 mg每2周一次。总体ORR为21.3%,1200 mg剂量组ORR为25.0%,PD-L1高表达(≥80%)患者ORR达85.7%。治疗相关不良事件发生率69%,≥3级为29%,无治疗相关死亡。

要点

  • 总体ORR 21.3%,1200 mg组ORR 25.0%。
  • PD-L1≥80%患者ORR达85.7%(6/7)。
  • ≥3级治疗相关不良事件发生率29%。

核心结论

  • bintrafusp alfa在含铂经治晚期NSCLC中显示出鼓舞人心的疗效和可管理的耐受性。

研究设计与样本

  • NCT02517398的1期开放标签扩展队列,纳入80例含铂治疗后进展且未接受过免疫治疗的晚期NSCLC患者,按1:1随机接受500 mg或1200 mg每2周一次。

主要发现

  • 全部患者ORR为21.3%(17/80)。
  • 500 mg组ORR为17.5%(7/40),1200 mg组ORR为25.0%(10/40)。
  • 1200 mg组中PD-L1阳性患者ORR为36.0%(10/27),PD-L1高表达(≥80%)患者ORR为85.7%(6/7)。
  • 治疗相关不良事件发生于69%(55/80),≥3级为29%(23/80),10%(8/80)因治疗相关不良事件停药,无治疗相关死亡。

关键数值与推荐

  • 主要终点为独立评审委员会依据RECIST 1.1评估的最佳总体缓解,以ORR衡量。
  • 中位随访时间为51.9周(IQR 19.6-74.0)。

临床怎么用

  • 对于含铂经治且未接受免疫治疗的晚期NSCLC,bintrafusp alfa 1200 mg每2周一次显示一定疗效,PD-L1高表达者缓解率更高。

局限性

  • 为1期扩展队列,样本量有限(80例),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β "trap") fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1), was evaluated in patients with advanced NSCLC. METHODS: This expansion cohort of NCT02517398, an ongoing, phase 1, open-label trial, includes 80 patients with advanced NSCLC that progressed after platinum doublet therapy or after platinum-based adjuvant or neoadjuvant treatment and those who also have not received previous immunotherapy. Patients were randomized at a one-to-one ratio to receive either bintrafusp alfa 500 mg or the recommended phase 2 dosage of 1200 mg every 2 weeks. The primary end point was the best overall response (by Response Evaluation Criteria in Solid Tumors 1.1 as adjudicated by independent review committee) and was assessed by the objective response rate (ORR). RESULTS: A total of 80 patients were randomized to receive bintrafusp alfa 500 or 1200 mg (n = 40 each). Median follow-up was 51.9 weeks (IQR, 19.6-74.0). The ORR in all patients was 21.3% (17 of 80). The ORR was 17.5% (seven of 40) and 25.0% (10 of 40) for the 500 mg dose and the 1200 mg dose (recommended phase 2 dose), respectively. At the 1200 mg dose, patients with PD-L1-positive and PD-L1-high (≥80% expression on tumor cells) had ORRs of 36.0% (10 of 27) and 85.7% (six of seven), respectively. Treatment-related adverse events occurred in 55 of the 80 patients (69%) and were graded as greater than or equal to 3 in 23 of the 80 patients (29%). Of the 80 patients, eight (10%) had a treatment-related adverse event that led to treatment discontinuation; no treatment-related deaths occurred. CONCLUSIONS: Bintrafusp alfa had encouraging efficacy and manageable tolerability in patients with NSCLC previously treated with platinum.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Paz-Ares L, Kim TM, Vicente D, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020. PMID: 32173464. doi:10.1016/j.jtho.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。